The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated substantial profits, the lapse of its exclusive rights opened the floodgates to off-brand versions, dramatically diminishing sales. This presents a unique dilemma for firms depending on related blockbuster medications,

The story of Viagra, and its parent company copyright, presents a complex case study for investors. Initially a blockbuster drug, producing billions in income, its exclusivity period created a deluge of lower-priced alternatives , significantly diminishing its market share . While specific businesses may try to capitalize on similar conditions , th